Treating nonthrombotic pulmonary hypertension from fibrosing mediastinitis
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tests a treatment for a rare lung condition called fibrosing mediastinitis, where scar tissue in the chest presses on the lung artery, causing high blood pressure in the lungs. The goal is to see if the treatment can improve your symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with fibrosing mediastinitis between November 2024 and November 2026.
- You are between 18 and 85 years old.
- You have symptoms like chest tightness, shortness of breath, or trouble exercising.
- Your CT scan shows that enlarged lymph nodes in your chest are pressing on your lung artery, and you have high blood pressure in your lungs (pulmonary hypertension) that matches your symptoms.
- You can sign a consent form and are willing to follow the study plan and come back for checkups for one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how lung scarring affects oxygen levels during sleep and exercise. It may help find better ways to monitor and treat breathing problems in people with fibrotic interstitial lung disease.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This trial studies whether rituximab can slow worsening lung scarring (interstitial lung disease) when there is an inflammatory component. You would get rituximab or a placebo (inactive treatment) in a blinded, randomized design to compare safety and effectiveness.
This trial tests a treatment to reduce certain antibodies in the blood that may be making your idiopathic pulmonary fibrosis (IPF) worse. The goal is to slow down the progression of the disease and help you breathe easier.
This trial tests whether starting anti-scarring medication early helps people with a type of lung scarring called fibrotic interstitial lung disease (ILD) that hasn't gotten worse. The goal is to see if it can prevent further damage and improve breathing.
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.